Abstract: A novel gastroretentive delivery system comprising a tablet comprising a pharmaceutical ingredient or diagnostic, which tablet comprises a gas releasing ingredient or a tandem of two gas releasing ingredients, an ingredient capable of unrestricted swelling in gastric fluid, an ingredient capable of limiting the unrestricted swelling and a hardening ingredient. The said system is based on the use of three different gastroretentive mechanisms: flotation, swelling and mechanical strength, the three mechanisms acting in a complimentary way. Processes for manufacturing same and methods of treatment are also disclosed.

Abstract: A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administrable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.

Abstract: The treatment of acute pain with a sufficient dosage by intranasal administration of fentanyl results in a time to onset of action comparable to intravenous administration and a significantly faster onset of action than nasal titration of fentanyl. The nasal administration of a sufficient amount of fentanyl to obtain pain relief has lower maximum plasma concentrations comparable to intravenous administration and results in lower rates of adverse events like respiratory depression, nausea and vomiting. Compositions for use in the method are also disclosed.

Abstract: The invention described herein relates to an oral transmucosal solid dosage form useful in treating nicotine addiction or as a nicotine substitute or replacement. By virtue of the formulation in combination with nicotine, the invention transmucosally delivers an effective amount of nicotine to the recipient while permitting the accomplishing of such, and manufacture of such, using a relatively small, convenient and orally comfortable dosage form (e.g., tablet) size.

Abstract: The invention provides effervescent composition comprising a bisphosphonate, an acidic compound, an alkaline effervescing component, and optionally an anti-ulcer agent and methods of treating osteoporosis in a mammal using the effervescent compositions.

Abstract: Fentanyl-containing dosage forms and methods using same are described. These dosage forms include substantially less fentanyl by weight than known oral formulation and have advantages in terms of reduced cost and reduced side effects. These dosage forms are intended for oral administration of fentanyl across the oral mucosa.

Abstract: The present invention is directed to effervescent cleaning compositions comprising a basic amino acid.

Abstract: An effervescent composition for reducing breath odors and preventing and/or reducing plaque buildup, deposits and/or formation on the teeth of pet animals. The effervescent composition includes at least one active agent adapted to reduce or destroy bacteria present in the mouth of the pet animal responsible for causing bad breath and plaque; and an effervescent component including a carbonate containing compound and an acidifying compound.

Abstract: The invention comprises a gastric device having a pouch formed from a degradable film. Preferably, the pouch contains a gas producing material. The gastric device hydrates within a patient's stomach and the gas producing material expands the device to a greater volume. Accordingly, the volume of the hydrated, expanded gastric devices occupy space in the stomach cavity and reduce the amount of food the patient will ingest before reaching the feeling of fullness. Preferably, the gastric device is made from food grade materials. The gastric device is configured to expand to a desired volume and then degrade after a residence time, allowing the device to be passed by the patient's normal digestive process.

Abstract: The present invention is directed to effervescent compositions comprising a basic amino acid.

Abstract: The present patent application relates to a keratin material coating kit comprising: a first composition comprising an aqueous phase, at least one alginic acid-based compound and at least one agent for complexing the said compound, the said agent being in the form of a water-insoluble salt and being capable of releasing a gas on contact with an acid having a pKa ranging from 1 to 6, and a second composition comprising an acid having a pKa ranging from 1 to 6.

Abstract: Skin care or cleansing implements are described containing a liquid, semi-solid or solid cleansing or skin treatment composition that is releasably associated with the implement. The composition is substantially nonaqueous and has a continuous and a discontinuous phase. Components of the discontinuous phase can react with each other or with water when water is blended with the nonaqueous cleansing or skin treatment composition during consumer use. Methods for treating the skin with the inventive implements are also described.

Abstract: A method of manufacturing a dosage form is described wherein a liquid solution of a biologically compatible polymer containing a suspension of particulate material that is insoluble in the polymer is supplied to a liquid supply tube (2) having an outlet (2a) and an electrical field is established between the outlet (2a) and a surface (19) spaced from the outlet (2a) to cause liquid issuing from the outlet to form a jet which dries to form a polymer fibre containing particles of the particulate material and which deposits onto the surface (19) to form a dosage which consists of said particulate containing fibre which fibre dissolves or disintegrates in a wet environment such as the mouth.

Abstract: Disclosed is an effervescent composition that includes menthol, eucalyptus oil, and an effervescent agent and that dissolves in water to form a clear solution.

Abstract: Particles having a tap density less than about 0.4 g/cm3 are formed by spray drying from a colloidal solution including a carboxylic acid or salt thereof, a phospholipid, a divalent salt and a solvent such as an aqueous-organic solvent. The colloidal solution can also include a therapeutic, prophylactic or diagnostic agent. Preferred carboxylic acids include at least two carboxyl groups. Preferred phospholipids include phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols, phophstidylserines, phosphatidylinositols and combinations thereof. The particles are suitable for pulmonary delivery.

Abstract: This invention relates to processes or methods for the production of compositions comprising extracts of black beans containing phenolics, such as polyphenols, flavonoids, and tannins, phytosterols, and triterpenoids such as saponins and other natural products with proven antioxidant capacity, colorant capacity, and uses thereof, e.g., as antioxidants, nutritional supplements, as food, cosmetic or pharmaceutical antioxidants or colorants, as antineoplastic or anti-cancer or anti-tumor preparations, e.g., to treat, prevent and/or inhibit cancers or cancer cell growth, such as hormone dependent or hormone independent tumors or cancers or cancer cells. such as mammalian mammary, prostate, colon, hepatic, leukemia cancer or cancer cell growth, as active ingredient(s) in compositions for lowering cholesterol or lowering oxidation of LDL or for inhibiting cholesterol synthesis (or the enzyme therefor), as an active ingredient(s) in compositions, e.g., nutritional supplements.

Abstract: The invention relates to an aqueous foam disinfectant comprised of a special surfactant system, which consists of non-ionic and amphoteric surfactants, and of a synergistic disinfectant constituent, which consists of an antimicrobial agent having amino groups and of at least one additional antimicrobial agent.

Abstract: A toilet training article in the form of a toilet training pad containing an effervescent agent is disclosed. The toilet training pad, which may be an insertable pad or integrated directly into an undergarment, contains an effervescent agent which releases gas upon being contacted by urine. The effervescent agent may be in the form of a compound containing a substantially inert gas, or may be a combination of compounds that, upon being contacted by urine, produce a gas.

Abstract: Provided, among other things, is a delivery module for water-based salicylic acid composition comprising: an aerosol delivery system; within the aerosol delivery system, the salicylic acid composition comprising 0.5% or more salicylic acid by weight, lipophilic component(s), and a frothing agent, the salicylic acid composition having a viscosity low enough to support aerosol delivery, and the salicylic acid composition effective to form a foam upon propellant-driven aerosol delivery; and within the aerosol delivery system, a propellant, wherein the salicylic acid composition is non-irritating and has a non-watery feel.

Abstract: This invention provides a tablet that effervesces and significantly warms the water that it is dissolved in. The effervescence acts to break up the tablet allowing an exothermic material to rapidly dissolve releasing its heat of solution. The invention is unique in that no organic acid is required to form a conventional effervescent couple.

Abstract: The invention comprises a gastric device having an outer region and a gas producing material. The gastric device hydrates within a patient's stomach and the gas producing material expands the device to a greater volume. Accordingly, the volume of the hydrated, expanded gastric devices occupy space in the stomach cavity and reduce the amount of food the patient will ingest before reaching the feeling of fullness. Preferably, the gastric device is made from food grade materials. The gastric device is configured to expand to a desired volume and then degrade after a residence time, allowing the device to be passed by the patient's normal digestive process.

Abstract: A pharmaceutical composition comprising at least one effervescent agent and a fibrate and a process for making such composition. The fibrate is fenofibrate and the effervescent agent are in a dosage form. The dosage form increases dissolution and absorption of fenofibrate in biological conditions where the form contacts acidic gastric fluid after oral administration.

Abstract: A composition for use in an aerosol inhaler, the composition comprising an active material, a propellant containing a hydrofluoroalkane (HFA), a cosolvent and further comprising a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler, filling of an aerosol container and use of the composition for the administration of active materials by inhalation.

Abstract: A method and accompanying apparatus that allows high concentrations of hydrogen peroxide for tooth whitening by use of an aerosol spray. The aerosol spray may be delivered through a mouthpiece that will direct the spray onto the teeth while inhibiting any escape of the spray to the lips and outside the moth. Also, in combination with antiplaque formulations, enhanced tooth whitening is effected.

Abstract: An foaming agent comprising a non-ionic surfactant, zwitterionic surfactant, and free of anionic surfactants which is suitable for use in personal care products, e.g., dentifrice compositions, e.g., for use in the treatment and/or alleviation of xerostomia.

Abstract: The use of mixtures of two, three or more straight-chain 1,2-alkanediols, the chains lengths of which (i) are different and (ii) in each case are in the range of 5 to 10 C atoms, as antimicrobial active compounds is described. Compared with the pure 1,2-alkanediols, the mixtures have a synergistically intensified action.

Abstract: Agricultural crops are protected from the growth of undesirable vegetation as well as nematode and insect infestations, by the application of hydrogen cyanamide in combination with a short-chain, water-soluble monocarboxylic acid, with improved pesticidal effect.

Abstract: The self-inflating article of the present invention contains a self-inflating personal care article contains, an inflatable bladder containing a substrate, at least one rupturable reservoir, a cleansing composition wherein said rupturable reservoir is positioned within the sack of the inflatable bladder. The self-inflating article surprisingly provides effective cleansing benefits to the skin and hair in a convenient, inexpensive, and sanitary manner.

Abstract: The invention relates to a pharmaceutical product comprising a dosing aerosol containing a propellant, an effective quantity of adsorbent, a pharmaceutically active substance, substance formulation or substance mixture, and a packaging enclosing the adsorbent and the dosing aerosol with the pharmaceutically active substance, substance formulation or substance mixture.

Abstract: This invention pertains to method and compositions for the purpose of increasing serum level of Erythropoietin (EPO) and the subsequent increase of red blood cells leading to an increase in athletic endurance.

Abstract: A stable non-alcoholic foamable pharmaceutical emulsion composition includes an unctuous emollient, at a concentration of about 0.5% to about 49% by weight; at least one multi-active agent; at a concentration of about 0.

Abstract: The current invention is directed to oligonucleotide sequences isolated from a sequence designated rbl-1 [SEQ ID NO. 19] that either kill or inhibit growth, or prevent the production of endogenously expressed toxin, of microorganisms. These ssDNA sequences, identified through use of a screening method, appear to act as modulators of essential growth functions which may act at the level of triplex formation, antisense inhibition, or as aptamers that alter gene function. The sequences, referred to as minimum functional regions, or MFRs, are useful inter alia as therapeutic agents for treatment of sepsis and other pathologies caused by microorganisms such as sepsis and/or in which microorganisms are contributory agents.

Abstract: An effervescent acidified rehydration preparation for administration in the drinking water of mammals and poultry includes an amount of a dry generally water soluble acidified electrolyte composition for treatment of dehydration in animals including mammals and poultry by oral administration in the drinking water of animals of interest and an amount of a pH balanced effervescent composition including an amount of one or more compatible water soluble organic acid species and an amount of one or more water soluble effervescent agents wherein effervescence occurs immediately upon the rehydration preparation being added to water.

Abstract: This invention provides a method for reducing the amount of osteopontin in an osteopontin-expressing cell comprising introducing into the cell a nucleic acid which specifically inhibits osteopontin expression in the cell. This invention also provides methods for inhibiting the onset of, and treating, osteopontin-related disorders, as well as compositions for practicing the same. This invention further provides methods for determining the amount of osteopontin in a sample, and a kit for practicing the same. This invention also provides methods for determining whether an agent reduces the amount of osteopontin in an osteopontin-expressing cell. Finally, this invention provides methods for treating a subject afflicted with a disorder mediated by an endogenous protein.

Abstract: Particles having a tap density less than about 0.4 g/cm3 are formed by spray drying from a colloidal solution including a carboxylic acid or salt thereof, a phospholipid, a divalent salt and a solvent such as an aqueous-organic solvent. The colloidal solution can also include a therapeutic, prophylactic or diagnostic agent. Preferred carboxylic acids include at least two carboxyl groups. Preferred phospholipids include phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols, phophstidylserines, phosphatidylinositols and combinations thereof. The particles are suitable for pulmonary delivery.

Abstract: Rapidly disintegrating preparations containing at least one active pharmaceutical ingredient and at least one excipient can be obtained by a simple process in which at least the predominant part of the complete composition of the ingredients for the preparation to be produced is granulated, the resulting granules and, where appropriate, the remainder of the ingredients are shaped in the presence of liquid virtually without pressure, and the resulting shaped articles are dried.

Abstract: An effervescent solid composition of matter is provided, which comprises, as an active component, a substance selected from chitosan, its derivatives and salts thereof and a second component capable of releasing CO2 in an acidic environment. Also, methods for treatment of a mammal suffering from a dermal wound, or for prophylactic or wound-healing treatment of lactating animals prone to develop or suffering from mastitis, are provided. The methods comprise the steps of: a) admixing said effervescent solid composition of matter with an aqueous liquid to form a solution or suspension thereof; b) contacting said animals with said solution or suspension to provide such treatment.

Abstract: A method for producing a preparation containing a bioactive substance, characterized in that it comprises forming a solid material containing the bioactive substance and a polymer, and contacting the solid material with a high pressure gas. The method allows the production of a preparation which is suppressed in excessive initial release of the bioactive substance immediately after the administration thereof, is capable of releasing a predetermined amount of the bioactive substance over a long period of time, and is extremely reduced in the deterioration of the bioactive substance and in the amount of a residual organic solvent.

Abstract: An effervescent preparation of glucosamine sulfate or a mixed salt thereof, suitable for preparing a drinkable medicine and applying a patient's daily dosage in a single dose. In a preferred embodiment of the invention, the preparation comprises a fruit acid, preferably citric acid, as acid component and for the improvement of storage-stability. A further preferred dosage form is effervescent tablets.

Abstract: The invention relates to pharmaceutical formulations and methods for preparing pharmaceutical formulations of histamine releasers. The present invention provides methods for determining the concentration of physiologically acceptable excipients for use in the formulations of the invention. The present invention also provides methods for suppressing pharmaceutically-induced histamine release by administering to an animal, the formulations of the present invention. A kit useful for preparing pharmaceutical formulations of histamine releasers is also provided.

Abstract: 1-Alkyn-3-ol compounds of the formula: where R1 is a saturated aliphatic hydrocarbon group containing from 1 to about 12 carbon atoms, and R2 is a hydrogen, are effective attractants for mosquitoes.

Abstract: A novel salt, creatine taurinate, and the compositions containing same (health foods, dietary supplements or drugs) are disclosed.

Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide alprazolam for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, alprazolam, and optional flavoring agent; formulation II: aqueous polar solvent, alprazolam, optionally flavoring agent, and propellant; formulation III: non-polar solvent, alprazolam, and optional flavoring agent; formulation IV: non-polar solvent, alprazolam, optional flavoring agent, and propellant; formulation V: a mixture of a polar solvent and a non-polar solvent, alprazolam, and optional flavoring agent; formulation VI: a mixture of a polar solvent and a non-polar solvent, alprazolam, optional flavoring agent, and propellant.

Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide atropine for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, atropine, and optional taste mask and/or flavoring agent; formulation II: aqueous polar solvent, atropine, optionally flavoring agent, and propellant; formulation III: non-polar solvent, atropine, and optional flavoring agent; and formulation IV: non-polar solvent, atropine, optional flavoring agent, and propellant; formulation V: a mixture of a polar and a non-polar solvent, atropine, and optional flavoring agent; formulation VI: a mixture of a polar and a non-polar solvent, atropine, optional flavoring agent, and propellant.

Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide ondansetron for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, ondansetron, and optional flavoring agent; formulation II: aqueous polar solvent, ondansetron, optionally flavoring agent, and propellant; formulation III: non-polar solvent, ondansetron, and optional flavoring agent; formulation IV: non-polar solvent, ondansetron, optional flavoring agent, and propellant; formulation V: a mixture of a polar solvent and a non-polar solvent, ondansetron, and optional flavoring agent; formulation VI: a mixture of a polar solvent and a non-polar solvent, ondansetron, optional flavoring agent, and propellant.

Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide sumatriptan for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, sumatriptan, and optional flavoring agent; formulation II: aqueous polar solvent, sumatriptan, optionally flavoring agent, and propellant; formulation III: non-polar solvent, sumatriptan, and optional flavoring agent; formulation IV: non-polar solvent, sumatriptan, optional flavoring agent, and propellant; formulation V: a mixture of a polar solvent and a non-polar solvent, sumatriptan, and optional flavoring agent; formulation VI: a mixture of a polar solvent and a non-polar solvent, sumatriptan, optional flavoring agent, and propellant.

Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation m: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.

Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation m: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.

Abstract: This invention relates generally to compositions for whitening human teeth, and more particularly, to compositions that do not contain hydrocarbon humectants and which, when applied onto the surface of teeth, act to whiten without damage to tooth surfaces. It does contain a hydrogel, defined as a gel that does not contain a hydrocarbon humectant. A hydrocarbon humectant is defined as a carbon, hydrogen and oxygen compound which is used to prevent the oral care composition from hardening upon exposure to air or a carbon, hydrogen and oxygen compound which is used as a carrier for ingredients of an oral care composition.

Abstract: Liquid aerosol formulations for generating aerosols include at least one high volatility carrier and a second component. In some embodiments, the liquid aerosol formulation is propellant free. An aerosol generating device generates an aerosol by passing liquid aerosol formulation through a flow passage heated to convert the liquid into a vapor, which is mixed with air to form an aerosol. In some embodiments, particles of the aerosol consist essentially of the second component. The aerosol generator can be incorporated in a hand held inhaler. The aerosol can be delivered to a targeted portion of the lung using the inhaler.